Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease
- PMID: 30854954
- DOI: 10.2174/1389201020666190311143554
Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Fatty Liver Disease
Abstract
Background: Red ginseng is a traditional medicine that has been used to treat numerous metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce NAFLD and liver inflammation compared with the effects reported for each individual product.
Method: db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively, and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein phosphorylation, and gene expression patterns.
Results: KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease in inflammatory cytokine secretion compared with the non-treated control mice. The same treatment was less successful in improving NAFLD parameters in the db/db mice while the combination of both products did not enhance their therapeutic potential.
Conclusion: The results of this study indicate that KRG and probiotics administration ameliorated NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation. Coadministration of both products did not enhance their efficacy, and further research should be conducted to clarify their mechanisms of action.
Keywords: Korean Red Ginseng (KRG); Non-Alcoholic Fatty Liver Disease (NAFLD); blood parameters; liver function; oral administration; probiotics..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Fermented Korean Red Ginseng Extract Enriched in Rd and Rg3 Protects against Non-Alcoholic Fatty Liver Disease through Regulation of mTORC1.Nutrients. 2019 Dec 4;11(12):2963. doi: 10.3390/nu11122963. Nutrients. 2019. PMID: 31817227 Free PMC article.
-
Korean red ginseng (Panax ginseng) inhibits obesity and improves lipid metabolism in high fat diet-fed castrated mice.J Ethnopharmacol. 2018 Jan 10;210:80-87. doi: 10.1016/j.jep.2017.08.032. Epub 2017 Aug 24. J Ethnopharmacol. 2018. PMID: 28844680
-
Effect of Korean Red Ginseng on metabolic syndrome.J Ginseng Res. 2021 May;45(3):380-389. doi: 10.1016/j.jgr.2020.11.002. Epub 2020 Nov 12. J Ginseng Res. 2021. PMID: 34025131 Free PMC article. Review.
-
Korean red ginseng extract prevents APAP-induced hepatotoxicity through metabolic enzyme regulation: the role of ginsenoside Rg3, a protopanaxadiol.Liver Int. 2013 Aug;33(7):1071-84. doi: 10.1111/liv.12046. Epub 2013 Jun 10. Liver Int. 2013. PMID: 23750847
-
A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease.Drug Des Devel Ther. 2025 Jan 8;19:83-96. doi: 10.2147/DDDT.S500719. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 39803604 Free PMC article. Review.
Cited by
-
The Efficacy of Panax ginseng for the Treatment of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Preclinical Studies.Nutrients. 2023 Jan 31;15(3):721. doi: 10.3390/nu15030721. Nutrients. 2023. PMID: 36771427 Free PMC article.
-
Intestinal microbiota in the treatment of metabolically associated fatty liver disease.World J Clin Cases. 2022 Nov 6;10(31):11240-11251. doi: 10.12998/wjcc.v10.i31.11240. World J Clin Cases. 2022. PMID: 36387806 Free PMC article. Review.
-
Effects of Ginsenoside Rb1 on the Crosstalk between Intestinal Stem Cells and Microbiota in a Simulated Weightlessness Mouse Model.Int J Mol Sci. 2024 Aug 12;25(16):8769. doi: 10.3390/ijms25168769. Int J Mol Sci. 2024. PMID: 39201456 Free PMC article.
-
Lactobacillus johnsonii BS15 combined with abdominal massage on intestinal permeability in rats with nonalcoholic fatty liver and cell biofilm repair.Bioengineered. 2021 Dec;12(1):6354-6363. doi: 10.1080/21655979.2021.1954134. Bioengineered. 2021. PMID: 34511035 Free PMC article.
-
Ginseng and its functional components in non-alcoholic fatty liver disease: therapeutic effects and multi-target pharmacological mechanisms.Front Pharmacol. 2025 Apr 9;16:1540255. doi: 10.3389/fphar.2025.1540255. eCollection 2025. Front Pharmacol. 2025. PMID: 40271056 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous